StockTipsArenaBeta

BUY Jubilant Pharmova Limited — Gaurav Sharma, Globe Capital Market

BUYJubilant Pharmova Limited
Jubilant Pharmova share price target & all analyst calls

byGaurav Sharma, Globe Capital MarketHorizon: NA (inferred Swing (≤2wk))14 May 2026via CNBC Awaaz.

Entry₹1,012Stated
Target₹1,075
Total upside +6.23% (call closed)
Stop loss₹975-3.66% risk
Exit₹97525 May 2026, 9:20 am
Stop-loss hit-3.66%
Follow Gaurav Sharma for new calls(27% target hit, 98 closed calls)Get alertsWatch JUBLPHARMA for new buy/sell callsGet alertsSee 105 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 22 Oct, 7:45 am IST
2 supporting2 neutral0 opposing
Supports the BUY call (2)

Jubilant Pharmova Limited announced the appointment of Mr. Priyavrat Bhartia as Managing Director, effective June 1, 2026.

NSE · Appointment·22 May · 2d ago

(opens in new tab)

Mr. Ashish Mukkirwar has been appointed as the Chief Financial Officer of the company, effective May 23, 2026.

NSE · Appointment·22 May · 2d ago

(opens in new tab)
Neutral / worth noting (2)

Jubilant Generics Limited, a subsidiary of Jubilant Pharmova, received an order from the Income-tax department for tax adjustments of Rs. 107.89 crores. The company believes the adjustments ignore fac

NSE · Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company·22 May · 2d ago

(opens in new tab)

Jubilant Pharmova Limited's Board of Directors approved the audited financial results for the quarter and financial year ended March 31, 2026. The Board also recommended a final dividend of Rs. 5 per

NSE · Outcome of Board Meeting·22 May · 2d ago

(opens in new tab)
Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Jubilant Pharmova

All analyst calls on Jubilant Pharmova

More from Gaurav Sharma, Globe Capital Market

Every call and its outcome